{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:49:09Z","timestamp":1761648549214,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.aohep.2021.100648","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T13:11:29Z","timestamp":1638537089000},"page":"100648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glycemic control, the unconsidered outcome in the treatment of nonalcoholic fatty liver disease"],"prefix":"10.1016","volume":"27","author":[{"given":"Diego","family":"Garc\u00eda-Compe\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Orsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2021.100648_bib0001","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"European association for the study of diabetes (EASD), European association for the study of obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of nonalcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2021.100648_bib0002","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00535-013-0911-1","article-title":"Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients","volume":"49","author":"Nakahara","year":"2014","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.aohep.2021.100648_bib0003","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3803\/EnM.2019.34.3.226","article-title":"Nonalcoholic fatty liver disease and diabetes: an epidemiological perspective","volume":"34","author":"Rhee","year":"2019","journal-title":"Endocrinol Metab"},{"key":"10.1016\/j.aohep.2021.100648_bib0004","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/liv.12912","article-title":"The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals","volume":"36","author":"Fukuda","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2021.100648_bib0005","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1479","article-title":"Pathogenesis of nonalcoholic steatohepatitis: an overview","volume":"4","author":"Parthasarathy","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.aohep.2021.100648_bib0006","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2021.100648_bib0007","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.aohep.2021.100648_bib0008","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicenter, double-blind, randomized, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2021.100648_bib0009","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/hep.31806","article-title":"Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease","volume":"74","author":"Alexopoulos","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2021.100648_bib0010","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2337\/dc09-0148","article-title":"Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis","volume":"33","author":"Hamaguchi","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.aohep.2021.100648_bib0011","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/hepr.13282","article-title":"Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with non-alcoholic fatty liver disease","volume":"49","author":"Tanaka","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.aohep.2021.100648_bib0012","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.clinre.2018.08.007","article-title":"Association of glycated hemoglobin with the risk of advanced fibrosis in nonalcoholic fatty liver disease patients without diabetes","volume":"43","author":"Yu","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.aohep.2021.100648_bib0013","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar- Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2021.100648_bib0014","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s13300-017-0362-4","article-title":"Utility and limitations of glycated hemoglobin (HbA1c) in patients with liver cirrhosis as compared with oral glucose tolerance test for diagnosis of diabetes","volume":"9","author":"Sehrawat","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.aohep.2021.100648_bib0015","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s11892-014-0548-3","article-title":"Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis and management","volume":"14","author":"Parrinello","year":"2014","journal-title":"Curr Diab Rep"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268121003501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268121003501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:43:28Z","timestamp":1761648208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268121003501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1665268121003501"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2021.100648","relation":{},"ISSN":["1665-2681"],"issn-type":[{"type":"print","value":"1665-2681"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycemic control, the unconsidered outcome in the treatment of nonalcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2021.100648","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100648"}}